Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer ...

MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...

Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary, ...

The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Modifi Biosciences Inc. has come a long way very quickly. Spun out of Yale University in 2021, it published data on DNA in ...